Antiangiogenic therapy in oncology: current status and future directions

The Lancet

Volumn 388, Issue 10043, 2016, Pages 518-529

  Jayson, Gordon C ^a   Kerbel, Robert ^b   Ellis, Lee M ^c   Harris, Adrian L ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; VASCULOTROPIN INHIBITOR; ANGIOPOIETIN 1; ANGIOPOIETIN RECEPTOR; ANGPT1 PROTEIN, HUMAN; CARBANILAMIDE DERIVATIVE; CEDIRANIB; LENVATINIB; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; SORAFENIB; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ABDOMINAL PAIN; ANTIANGIOGENIC THERAPY; BLEEDING; BREAST CANCER; CLEAR CELL CARCINOMA; COLORECTAL CANCER; DIARRHEA; ESOPHAGUS CANCER; FATIGUE; FISTULA; GLIOMA; HAIR DISEASE; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INTESTINE PERFORATION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; MALAISE; MEDLINE; NEUROENDOCRINE TUMOR; NONHUMAN; ONCOLOGY; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRECLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEINURIA; REVIEW; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THYROID CANCER; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROCEDURES; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-1; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; QUINOLINES; RECEPTOR, TIE-2; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84989159343     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)01088-0     Document Type: Review

References (113)

1. Folkman, J, Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971), 1182–1186.
2. Butler, JM, Kobayashi, H, Rafii, S, Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 10 (2010), 138–146.
3. Kerbel, RS, Tumor angiogenesis. N Engl J Med 358 (2008), 2039–2049.
4. Ferrara, N, Kerbel, RS, Angiogenesis as a therapeutic target. Nature 438 (2005), 967–974.
5. Bridges, EM, Harris, L, The angiogenic process as a therapeutic target in cancer. Biochem Pharmacol 81 (2011), 1183–1191.
6. Monk, BJ, Poveda, A, Vergote, I, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15 (2014), 799–808.
7. Ridgway, J, Zhang, G, Wu, Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444 (2006), 1083–1087.
8. Kangsamaksin, T, Murtomaki, A, Kofler, NM, et al. Notch Decoys that Selectively Block Dll/Notch or Jagged/Notch Disrupt Angiogenesis by Unique Mechanisms to Inhibit Tumor Growth. Cancer Discov 5 (2015), 182–197.
9. Escudier, B, Szczylik, C, Porta, C, Gore, M, Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol 9 (2012), 327–337.
10. Shaked, Y, Ciarrocchi, A, Franco, M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313 (2006), 1785–1787.
11. Carmeliet, P, Jain, RK, Molecular mechanisms and clinical applications of angiogenesis. Nature 47 (2011), 298–307.
12. vFerrara, N, VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2 (2002), 795–803.
13. Ferrara, N, Carver-Moore, K, Chen, H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380 (1996), 439–442.
14. Boehm, T, Folkman, J, Browder, T, O'Reilly, MS, Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 (1997), 404–407.
15. Herbst, RS, Hess, KR, Tran, HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20 (2002), 3792–3803.
16. Kung, AL, Practices and pitfalls of mouse cancer models in drug discovery. Adv Cancer Res 96 (2007), 191–212.
17. Francia, G, Cruz-Munoz, W, Man, S, Xu, P, Kerbel, RS, Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 11 (2011), 135–141.
18. Guerin, E, Man, S, Xu, P, Kerbel, RS, A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res 73 (2013), 2743–2748.
19. Singh, M, Lima, A, Molina, R, et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 28 (2010), 585–593.
20. Tentler, JJ, Tan, AC, Weekes, CD, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 9 (2012), 338–350.
21. Batchelor, TT, Sorensen, AG, di Tomaso, E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007), 83–95.
22. Winkler, F, Kozin, SV, Tong, RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6 (2004), 553–563.
23. Van der Veldt, AA, Lubberink, M, Bahce, I, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21 (2012), 82–91.
24. Szabo, V, Bugyik, E, Dezso, K, et al. Mechanism of tumour vascularization in experimental lung metastases. J Pathol 235 (2015), 384–396.
25. Pezzella, F, Di Bacco, A, Andreola, S, Nicholson, AG, Pastorino, U, Harris, AL, Angiogenesis in primary lung cancer and lung secondaries. Eur J Cancer 32A (1996), 2494–2500.
26. Sitohy, B, Nagy, JA, Jaminet, SC, Dvorak, HF, Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy. Cancer Res 71 (2011), 7021–7028.
27. Burger, RA, Brady, MF, Bookman, MA, et al., the Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365 (2011), 2473–2483.
28. Hurwitz, H, Fehrenbacher, L, Novotny, W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004), 2335–2342.
29. Sandler, A, Gray, R, Perry, MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006), 2542–2550.
30. Simpkins, F, Belinson, JL, Rose, PG, Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 107 (2007), 118–123.
31. Schmidinger, M, Bellmunt, J, Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 36 (2010), 416–424.
32. Cameron, D, Brown, J, Dent, R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 14 (2013), 933–942.
33. de Gramont, A, Van Cutsem, E, Schmoll, HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 13 (2012), 1225–1233.
34. Perren, TJ, Swart, AM, Pfisterer, J, et al., the ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365 (2011), 2484–2496.
35. Corrie, PG, Marshall, A, Dunn, JA, et al. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncol 15 (2014), 620–630.
36. Sun, M, Larcher, A, Karakiewicz, PI, Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence. Int J Nephrol Renovasc Dis 7 (2014), 401–407.
37. Rini, BI, Bellmunt, J, Clancy, J, et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 32 (2014), 752–759.
38. Hutson, TE, Escudier, B, Esteban, E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 32 (2014), 760–767.
39. Aghajanian, C, Blank, SV, Goff, BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30 (2012), 2039–2045.
40. Pujade-Lauraine, E, Hilpert, F, Weber, B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 32 (2014), 1302–1308.
41. Ledermann, JA, Perren, TJ, Raja, FA, et al., the ICON6 Collaborators. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. Eur J Cancer 49 (2013), S5–S6 (abstr LBA10).
42. Mancuso, MR, Davis, R, Norberg, SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116 (2006), 2610–2621.
43. Liu, JF, Barry, WT, Birrer, M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 15 (2014), 1207–1214.
44. Tewari, KS, Sill, MW, Long, HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370 (2014), 734–743.
45. Llovet, JM, Ricci, S, Mazzaferro, V, et al., the SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008), 378–390.
46. Cheng, AL, Kang, YK, Chen, Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 (2009), 25–34.
47. Cainap, C, Qin, S, Huang, WT, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 33 (2015), 172–179.
48. Johnson, PJ, Qin, S, Park, JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31 (2013), 3517–3524.
49. Kudo, M, Imanaka, K, Chida, N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47 (2011), 2117–2127.
50. Kudo, M, Han, G, Finn, RS, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatology 60 (2014), 1697–1707.
51. Bruix, J, Takayama, T, Mazzaferro, V, et al., on behalf of the STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 16 (2015), 1344–1354.
52. Brose, MS, Nutting, CM, Jarzab, B, et al., the DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384 (2014), 319–328.
53. Schlumberger, M, Tahara, M, Wirth, LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372 (2015), 621–630.
54. Mulligan, LM, RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer 14 (2014), 173–186.
55. Kurzrock, R, Sherman, SI, Ball, DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29 (2011), 2660–2666.
56. Raymond, E, Dahan, L, Raoul, JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364 (2011), 501–513.
57. Yao, JC, Shah, MH, Ito, T, et al. the RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364 (2011), 514–523.
58. Subbiah, V, Slopis, J, Hong, DS, et al. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. J Clin Oncol 30 (2012), e64–e68.
59. Dupuis-girod, S, Ginon, I, Saurin, JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 307 (2012), 948–955.
60. Fuchs, CS, Tomasek, J, Yong, CJ, et al., the REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383 (2014), 31–39.
61. Wilke, H, Muro, K, Van Cutsem, E, et al., the RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15 (2014), 1224–1235.
62. Giantonio, BJ, Catalano, PJ, Meropol, NJ, et al., the Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25 (2007), 1539–1544.
63. Van Cutsem, E, Tabernero, J, Lakomy, R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30 (2012), 3499–3506.
64. Schmoll, HJ, Cunningham, D, Sobrero, A, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol 30 (2012), 3588–3595.
65. Hoff, PM, Hochhaus, A, Pestalozzi, BC, et al. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). J Clin Oncol 30 (2012), 3596–3603.
66. Grothey, A, Van Cutsem, E, Sobrero, A, et al., the CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 (2013), 303–312.
67. Bennouna, J, Sastre, J, Arnold, D, et al., the ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14 (2013), 29–37.
68. Willett, CG, Duda, DG, di Tomaso, E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 27 (2009), 3020–3026.
69. Batchelor, TT, Duda, DG, di Tomaso, E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28 (2010), 2817–2823.
70. Reardon, DA, Fink, KL, Mikkelsen, T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26 (2008), 5610–5617.
71. Gilbert, MR, Dignam, JJ, Armstrong, TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370 (2014), 699–708.
72. Miller, KD, Chap, LI, Holmes, FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005), 792–799.
73. Fakhrejahani, E, Toi, M, Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials. Jpn J Clin Oncol 44 (2014), 197–207.
74. Earl, HM, Hiller, L, Dunn, JA, et al., the ARTemis Investigators. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol 16 (2015), 656–666.
75. Gerber, B, Loibl, S, Eidtmann, H, et al., the German Breast Group Investigators. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol 24 (2013), 2978–2984.
76. Reck, M, von Pawel, J, Zatloukal, P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27 (2009), 1227–1234.
77. Liang, W, Wu, X, Hong, S, et al. Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses. PLoS One, 9, 2014, e109757.
78. Garon, EB, Ciuleanu, T-E, Arrieta, O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384 (2014), 665–673.
79. Seto, T, Kato, T, Nishio, M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 15 (2014), 1236–1244.
80. Kindler, HL, Niedzwiecki, D, Hollis, D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28 (2010), 3617–3622.
81. Van Cutsem, E, Vervenne, WL, Bennouna, J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27 (2009), 2231–2237.
82. Michaelson, MD, Oudard, S, Ou, Y-C, et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol 32 (2014), 76–82.
83. Heidenreich, A, Rawal, SK, Szkarlat, K, et al. A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer. Ann Oncol 24 (2013), 329–336.
84. Wedam, SB, Low, JA, Yang, SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24 (2006), 769–777.
85. Willett, CG, Boucher, Y, di Tomaso, E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004), 145–147.
86. O'Connor, JP, Jayson, GC, Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?. Clin Cancer Res 18 (2012), 6588–6598.
87. Emblem, KE, Mouridsen, K, Bjornerud, A, et al. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med 19 (2013), 1178–1183.
88. Backen, A, Renehan, AG, Clamp, AR, et al. The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. Clin Cancer Res 20 (2014), 4549–4558.
89. Collinson, F, Hutchinson, M, Craven, RA, et al. Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clinical Cancer Res 19 (2013), 5227–5239.
90. Hasan, J, Byers, R, Jayson, GC, Intra-tumoural microvessel density in human solid tumours. Br J Cancer 86 (2002), 1566–1577.
91. Tolaney, SM, Boucher, Y, Duda, DG, et al. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci USA 112 (2015), 14325–14330.
92. Lambrechts, D, Claes, B, Delmar, P, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 13 (2012), 724–733.
93. Kerbel, RS, Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 13 (1991), 31–36.
94. Ellis, LM, Hicklin, DJ, Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 14 (2008), 6371–6375.
95. Bergers, G, Hanahan, D, Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8 (2008), 592–603.
96. Casanovas, O, Hicklin, DJ, Bergers, G, Hanahan, D, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8 (2005), 299–309.
97. Huang, D, Ding, Y, Zhou, M, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70 (2010), 1063–1071.
98. Rigamonti, N, Kadioglu, E, Keklikoglou, I, Wyser Rmili, C, Leow, CC, De Palma, M, Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep 8 (2014), 696–706.
99. Rapisarda, A, Hollingshead, M, Uranchimeg, B, et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 8 (2009), 1867–1877.
100. Yu, JL, Rak, JW, Coomber, BL, Hicklin, DJ, Kerbel, RS, Effect of p53 status on tumor response to antiangiogenic therapy. Science 295 (2002), 1526–1528.
101. Shojaei, F, Wu, X, Malik, AK, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 25 (2007), 911–920.
102. Nagy, JA, Dvorak, HF, Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets. Clin Exp Metastasis 29 (2012), 657–662.
103. Rubenstein, JL, Kim, J, Ozawa, T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2 (2000), 306–314.
104. Valiente, M, Obenauf, AC, Jin, X, et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156 (2014), 1002–1016.
105. Tang, TC, Man, S, Xu, P, et al. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia 12 (2010), 928–940.
106. Grothey, A, VEGF inhibition beyond tumour progression. Lancet Oncol 14 (2013), 2–3.
107. von Minckwitz, G, Puglisi, F, Cortes, J, et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol 15 (2014), 1269–1278.
108. Smith, DC, Eisenberg, PD, Manikhas, G, et al. A Phase I dose escalation and expansion study of the anticancer stem cell agent Demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res 20 (2014), 6295–6303.
109. Gerald, D, Chintharlapalli, S, Augustin, HG, Benjamin, LE, Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res 73 (2013), 1649–1657.
110. Brooks, AN, Kilgour, E, Smith, PD, Molecular Pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 18 (2012), 1855–1862.
111. Blumenschein, GR Jr, Mills, GB, Gonzalez-Angulo, AM, Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol 30 (2012), 3287–3296.
112. Motz, GT, Coukos, G, The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 11 (2011), 702–711.
113. Hodi, FS, Lawrence, D, Lezcano, C, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2 (2014), 632–642.